Search

Heyue Zhou

from San Diego, CA
Age ~54
Get Report
Also known as:
Zhou Heyue
Connected to:
Aihua Zhou, 47Aishi Zhou, 74Angela Zhou, 56Anqi Zhou, 57Anqiang Zhou, 80Bonnie Zhou, 65Boyu Zhou, 34Calvin J Zhou, 40Carolyn L Zhou, 27Cecilia Zhou, 55

Heyue Zhou Phones & Addresses

  • San Diego, CA
  • Chula Vista, CA
  • 10936 Via Banco, San Diego, CA 92126

Work

Company: The scripps research institute Position: Research associate

Education

Degree: phd School / High School: University of Science and Technology of China 2001 to 2005 Specialities: biology

Skills

Protein Chemistry • Molecular Biology • Protein Purification • Protein Engineering • Molecular Cloning • Protein Expression • Biochemistry • Antibodies • Phage Display • Cell Biology • Elisa • Western Blotting • Sds Page • Assay Development • High Throughput Screening • Purification • Immunofluorescence • Structural Biology

Industries

Research

Resumes

Resumes

Heyue Zhou Photo 1

Research Associate At The Scripps Research Institute

View page
Location:
San Diego, CA
Industry:
Research
Work:
The Scripps Research Institute
Research Associate
Education:
University of Science and Technology of China 2001 - 2005
phd, biology
Skills:
Protein Chemistry
Molecular Biology
Protein Purification
Protein Engineering
Molecular Cloning
Protein Expression
Biochemistry
Antibodies
Phage Display
Cell Biology
Elisa
Western Blotting
Sds Page
Assay Development
High Throughput Screening
Purification
Immunofluorescence
Structural Biology

Publications

Us Patents

Antigen Binding Proteins That Bind Dll-4

View page
US Patent:
20130323248, Dec 5, 2013
Filed:
May 28, 2013
Appl. No.:
13/903793
Inventors:
Yanliang Zhang - San Diego CA, US
Heyue Zhou - San Diego CA, US
Randy Gastwirt - San Diego CA, US
Assignee:
Sorrento Therapeutics Inc. - San Diego CA
International Classification:
C07K 16/22
US Classification:
4241351, 5303892, 5303873, 4241581
Abstract:
There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.

Antigen Binding Proteins That Bind Pd-L1

View page
US Patent:
20130323249, Dec 5, 2013
Filed:
May 31, 2013
Appl. No.:
13/907685
Inventors:
Heyue Zhou - San Diego CA, US
Randy Gastwirt - San Diego CA, US
Barbara A. Swanson - Encinitas CA, US
John Dixon Gray - San Diego CA, US
Gunnar F. Kaufmann - San Diego CA, US
Assignee:
Sorrento Therapeutics Inc. - San Diego CA
International Classification:
C07K 16/28
US Classification:
4241351, 5303891, 4241721, 5303873
Abstract:
There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.

Antigen Binding Proteins That Bind Igf1R

View page
US Patent:
20130344069, Dec 26, 2013
Filed:
Jun 12, 2013
Appl. No.:
13/916129
Inventors:
Heyue Zhou - San Diego CA, US
Guodi Lu - San Diego CA, US
International Classification:
C07K 16/30
US Classification:
4241351, 5303897, 5303873, 4241741
Abstract:
There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF1R related disorders or conditions, including various inflammatory disorders and various cancers.

Antigen Binding Proteins That Bind Ccr2

View page
US Patent:
20130344070, Dec 26, 2013
Filed:
Jun 21, 2013
Appl. No.:
13/924501
Inventors:
Barbara A. Swanson - Encinitas CA, US
John Dixon Gray - San Diego CA, US
Heyue Zhou - San Diego CA, US
Guodi Lu - San Diego CA, US
International Classification:
C07K 16/28
US Classification:
4241351, 5303896, 5303873, 4241731
Abstract:
There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.

Method For Displaying Antibodies

View page
US Patent:
20110250642, Oct 13, 2011
Filed:
Apr 12, 2011
Appl. No.:
13/085381
Inventors:
Henry Ji - San Diego CA, US
Heyue Zhou - San Diego CA, US
Yanliang Zhang - San Diego CA, US
Charles Rodi - Del Mar CA, US
International Classification:
C12P 21/00
US Classification:
435 696
Abstract:
There is disclosed vector designs, constructs and approaches to construct antibody libraries that display antibodies, such as full-length immunoglobulins, single chain antibody (SCA) scFv, or Fab on the host cell surface. There is also disclosed screening approaches to isolate desired antibody binders from above mentioned antibody libraries for selective antibody targets.

Compositions And Methods Comprising An Anti-Cd47 Antibody In Combination With A Tumor Targeting Antibody

View page
US Patent:
20210221886, Jul 22, 2021
Filed:
Dec 4, 2020
Appl. No.:
17/112587
Inventors:
- San Diego CA, US
Heyue Zhou - San Diego CA, US
Christophe Pedros - San Diego CA, US
International Classification:
C07K 16/28
A61P 35/02
A61K 9/00
Abstract:
The present disclosure provides compositions and methods comprising a first antibody comprising a fully human anti-CD47 antibody and a second antibody comprising an Fc portion that binds an Fcγ receptor on an effector cell. In various embodiments the anti-CD47 antibody used in the methods and compositions exhibits a low level of binding to red blood cells and does not induce hemagglutination even at high concentrations of antibody. In some embodiments, the second antibody comprises a tumor-targeting antibody including an antibody that binds CD20, PD-L1, CD38 or SLAMF7 antigens. The combination of the fully human anti-CD47 antibody and the second antibody can decrease cancer burden in a subject.

Antigen Binding Proteins That Bind Pd-L1

View page
US Patent:
20210147539, May 20, 2021
Filed:
Jan 13, 2021
Appl. No.:
17/148450
Inventors:
- San Diego CA, US
Heyue Zhou - San Diego CA, US
Assignee:
Sorrento Therapeutics, Inc. - San Diego CA
International Classification:
C07K 16/28
C07K 16/30
Abstract:
There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.

Variant Antibody That Binds Cd38

View page
US Patent:
20210130484, May 6, 2021
Filed:
Dec 18, 2020
Appl. No.:
17/127766
Inventors:
- San Diego CA, US
Heyue Zhou - San Diego CA, US
Jian Cao - San Diego CA, US
Assignee:
Sorrento Therapeutics, Inc. - San Diego CA
International Classification:
C07K 16/28
Abstract:
The present disclosure provides anti-CD38 IgG class antibody having improved ability to be manufactured at higher yields compared to the parent antibody having the original wild type sequence. The present disclosure provides a mutated antibody light chain that reduces cleavage heterogeneity for improved production of a homogeneous population of antibody light chains.
Control profile
Heyue Zhou from San Diego, CA, age ~54 Get Report